Open Orphan

Europe’s leading rare disease

EPIC: ORPH

SEGMENT: UK Standard List

WEBSITE: www.openorphan.com

All data delayed by at least 15 minutes.

Who are Open Orphan

Open Orphan was founded in 2017, with the goal of becoming Europe’s leading rare disease and orphan drug focused pharma services company by a management team with extensive industry and financial expertise. Open Orphan is listed on both the London and Dublin stock exchanges.

We are developing our European rare / orphan pharma services business by consolidating a number of smaller services companies in this highly fragmented but high margin sector. These companies are primarily operating in our initial core areas of regulatory, reimbursement, product launch and communications.

We have developed a strong pipeline of potential acquisitions and are in advanced discussions with a large number of these. Post IPO, we aim to offer a complete platform of services in Europe primarily in the areas of regulatory approval, reimbursement, product launch and communications.

MEET THE TEAM

Cathal Friel

CEO

Professor Brendan Buckley

Chairman

Maurice Treacy

Director

Website

Latest News

Have your say….

Do you want to know more about Open Orphan?

Do you want to stay connected with the company?

Do you just want to have your say…..

Pello Spotlight will relay your comments back to Open Orphan and give you the

chance to stay connected.

LOG IN   OR   Sign Up   to accept and place an order

Cornhill Capital Limited offers investments and services to clients, which are primarily considered to be high risk investments. Some investments such as contracts for difference use leverage which can magnify gains but equally can magnify losses. Leveraged products may lose investors more than the amount they initially invested. This website is provided for information purposes only. It is not an offer to sell, or a solicitation of an offer to buy, any security, nor enter into any agreement or contract with Cornhill Capital Limited. All information provided is indicative and subject to market conditions and availability. Not all financial products are suitable for all investors. Before entering into any transaction you should ensure that you understand and have made an independent assessment of the suitability and appropriateness of the transaction into which you are entering and the nature and extent of your exposure to risk of loss in light of your own objectives, financial and operational resources and other relevant circumstances. You should take such independent investigations and such professional advice as you consider necessary or appropriate for such purpose. Past performance is no indicator of future success.